Cannabis

Legalized medical cannabis five years on - Releaf reveals impact of negative stigma and lack of legal knowledge

27-Nov-2023 By Liza Laws

It is five years this month since a ground-breaking change in UK healthcare history happened – with doctors being able to prescribe cannabis-based medicines for the first time.

Celadon's new contract with European medical cannabis company has potential to generate millions for product

16-Nov-2023 By Liza Laws

Celadon Pharmaceuticals announced today (November 16) that it has secured a new sales contract with an unnamed European medical cannabis company.

Cannabis-based, non-cancer, chronic pain trial approved by NHS ethics committee

01-Aug-2023 By Liza Laws

The National Health Service (NHS) research ethics committee has approved a non-cancer chronic pain clinical trial being rolled out by private health clinic LVL Health.

Anebulo Pharmaceuticals: providing an effective antidote for cannabis intoxication

29-Jun-2023 By Isabel Cameron

Anebulo Pharmaceuticals is currently developing a new, first-of-its-kind drug, ANEB-001, intended to rapidly reverse the negative effects of acute cannabinoid intoxication (ACI) within one hour of administration. The treatment is a cannabinoid receptor...

Cannabinoid receptor given approval for trial after benefits revealed for chemo and IBS patients

08-Jun-2023 By Liza Laws

A cannabinoid receptor, that has shown potential as an effective treatment for chemotherapy induced peripheral neuropathy (CIPN) has been given approval for a phase 1 clinical trial by the Medicines and Healthcare Products Regulatory Agency (MRHA) and...

Interview: Arthur Wakeley, MD of Celadon, the first UK company cleared to make medical cannabis

07-Feb-2023 By Liza Laws

As reported on January 17, Celadon Pharmaceuticals Plc was the first company to clear the regulations in the UK to make medical cannabis.

Formulation technology improving CBD uptake bought out

20-Feb-2020 By Vassia Barba

Bioavailability of water insoluble compounds, such as CBD, enhanced up to 15 times with the technology of Solmic, leading to its acquisition by Betterlife.

Sanofi in manufacturing deal for cannabinoid overdose treatment

01-Aug-2019 By Vassia Barba

Sanofi to manufacture and commercialize Opiant’s investigational treatment for acute cannabinoid overdose, which could become the first treatment for the condition.

Lonza enters a collaborative agreement with Auxly for capsule formulation

01-Jul-2019 By Maggie Lynch

Lonza will supply Auxly with materials and proprietary manufacturing equipment for capsule filling and sealing through collaborative agreement.

GW: Inventory and capacity set for ‘even the most aggressive of demand forecast’

28-Nov-2018 By Flora Southey

GW Pharma has told investors its capacity is “more than sufficient” to meet launch requirements in Europe next year, where the firm’s CBD medicine Epidiolex is under review.

Axim expands IP with cannabinoid suppository patent

01-Nov-2018 By Flora Southey

Axim predicts high demand from patients with symptoms and conditions that prevent swallowing.

Axim Biotech ‘closes GMP circle’ with manufacturing license for cannabinoids

16-Oct-2018 By Flora Southey

The Dutch Ministry of Health has granted Axim Biotech a manufacturing license to produce cannabis-derived candidates for clinical trials.

Johnson Matthey offers new synthetic method for ‘ultra-pure’ CBD

26-Sep-2018 By Flora Southey

The synthetic process produces a crystalline powder that can be particle size-adjusted for formulation requirements, says JM.

Has Big Pharma’s ‘inevitable entrance’ into the cannabis space arrived?

03-Sep-2018 By Flora Southey

Pfizer, GW Pharma, Merck & Co, and Sanofi-Aventis are among the leading cannabis patent holders in Canada, says report.

Lexaira Bioscience demonstrates high bioavailability in CBD platform

14-Aug-2018 By Maggie Lynch

Lexaira Bioscience says its DehydraTECH platform has demonstrated significant improvements to the bioavailability of cannabinoids, and could be applied to other pharmaceuticals.

GW prepping for mid-2018 CBD epilepsy candidate approval in US

05-Dec-2017 By Dan Stanton

Cannabinoid firm GW Pharmaceuticals says it is “inspection ready” as it prepares for potential US approval of its epilepsy candidate Epidiolex (cannabidiol or CBD).

Mexico legalizes medical marijuana: a boon for pharma?

28-Jun-2017 By Flora Southey

Mexican president Pena Nieto has legalised the cultivation, production and use of cannabis products with less than 1% THC for medical uses in Mexico.

Cure & cancer: cannabis molecule blend research

12-Jun-2017 By Flora Southey

Cure Pharmaceutical has entered into a strategic collaboration to test and develop potential cancer therapeutics utilising a blend of the cannabis plant-derived terpenes. 

Opioid API firm Noramco moves into cannabinoids

08-Mar-2017 By Gareth Macdonald

Noramco has added cannabinoids to its portfolio of opioid APIs.

Nemus hires Catalent to formulate second chemo-induced nausea drug

06-Mar-2017 By Gareth Macdonald

Catalent Pharma Solutions has been hired to formulate Nemus Bioscience’s synthetic cannabinoid based chemotherapy induced nausea drug.

Tilray begins shipping medical marijuana to more countries

20-Feb-2017 By Dani Bancroft

Medical marijuana developer Tilray has begun shipping to overseas patients and trial sites outside Canada after partnering with local distributors to comply with regional regulations.

Pot luck? Medical marijuana's 'questionable quality’ no threat to pharma R&D

08-Feb-2017 By Dan Stanton

Pharma firms using cannabis-derived ingredients have hit out at the lack of standardization and the questionable quality of medical marijuana.

GMP-status 'a major step' for medical marijuana recognition, Bedrocan

26-Jan-2017 By Dan Stanton

The GMP certification of a Dutch cannabis production facility is a “major step” in bringing medicinal marijuana to the level of evidence based medicines, says Bedrocan.

Reefer Gladness? DEA OKs Catalent to supply marijuana from Missouri plant

09-Dec-2015 By Dan Stanton

Catalent has registered a facility in Missouri with the US DEA to import cannabis extracts in dosage form for clinical trial studies.

Axim to build Dutch facility for cannabinoid-based chewing gum drug

04-Dec-2014 By Dan Stanton

A company developing a pharmaceutical chewing gum containing cannabinoids extracted from marijuana has announced plans to build a manufacturing facility in the Netherlands.

Can a biz grow cannabis to provide APIs for its pipeline? France says 'oui'

15-Jan-2014 By Dan Stanton

Drugs containing APIs derived from cannabis plants are a far cry from the non-clinical approach of marijuana dispensaries, says GWPharma, as France approves Sativex.